Singapore markets closed

Straits Times Index
3,306.02
+6.02(+0.18%)
Nikkei
38,596.47
-36.55(-0.09%)
Hang Seng
18,028.52
-306.80(-1.67%)
FTSE 100
8,237.72
-34.74(-0.42%)
Bitcoin USD
64,447.86
+321.78(+0.50%)
CMC Crypto 200
1,351.69
-8.63(-0.63%)

PCVX Jul 2024 75.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

4.9500

+1.4500

(+41.43%)

At close: 03:52PM EDT

Loading interactive chart…

Simply Wall St.
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswire
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen